A single platelet protein explains why exercise, the longevity protein Klotho, and young plasma transfusion rejuvenate memory, immunity, and bone marrow in aged mice, and why the same protein can trigger blood clots

A single platelet protein explains why exercise, the longevity protein Klotho, and young plasma transfusion rejuvenate memory, immunity, and bone marrow in aged mice, and why the same protein can trigger blood clots

A review in Frontiers in Immunology, published on September 2, brings together three independent 2023 studies into a unified model: physical exercise, Klotho protein, and young plasma all raise levels of the platelet-derived protein PF4 in aged mice, and PF4 in turn reduces brain inflammation, accelerates the growth of new neurons, and repairs immune cells and bone marrow. The same review identifies PF4's ability to cause blood clots as the primary risk for any therapeutic application.

Experiments conducted between 2005 and 2014 showed that surgically joining the circulatory systems of an old and a young mouse (parabiosis), or transfusing young plasma into an old mouse, partially restored aging muscles, liver, and brain. Twelve weeks of such pairing extended the lifespan of old mice by roughly 10%. Transfusing young plasma into humans faces the obstacles of donor scarcity and rejection risk, so the field of geroscience shifted toward identifying the specific molecule responsible.

In 2023, three independent groups converged on the same protein from different directions. The first showed that removing platelets from young plasma abolished its ability to improve memory in aged mice, meaning the effect is carried by the platelets themselves, not by the cell-free plasma. The second found that the longevity protein Klotho (overexpression of which extends mouse lifespan by roughly 30%) mildly activates platelets and causes them to release PF4. In mice lacking the PF4 gene, Klotho still improved memory, indicating that Klotho operates through additional pathways beyond PF4. The third group demonstrated the opposite dependence: four days of running elevated circulating PF4, and in mice lacking the PF4 gene, running no longer increased hippocampal neurogenesis at all. In this context, the entire effect rested on PF4 alone.

Purified PF4 injected into aged mice reproduced the benefits of young plasma through two receptors: CXCR3 (on immune cells) and LDLR (the receptor cells normally use to take up cholesterol from the blood). PF4 reduced the number of activated brain microglia by roughly one third, accelerated the growth of new hippocampal neurons, shifted aged T-cells toward a younger profile, and kept bone marrow stem cells in a quiescent state, lowering their accumulated DNA damage. How PF4 reaches the brain is not fully resolved: one laboratory detected it directly in hippocampal tissue after intravenous injection, while another did not, even though memory still improved. PF4 likely acts both directly within the brain and indirectly by calming peripheral immune activity, which otherwise sends more inflammatory signals into the central nervous system.

The harmful side of PF4 operates through different biochemistry than its cognitive benefits. PF4 binds strongly to heparin, an anticoagulant drug, and the resulting complex sometimes provokes antibodies that attack platelets, a condition known as heparin-induced thrombocytopenia, which causes dangerous clotting. Separately, PF4 binds the c-Mpl receptor on platelets and directly triggers their aggregation. In skin, liver, bone marrow, and cardiac tissue of animals, PF4 also promotes fibrosis (scarring). In older humans, platelets are already more reactive, so additional PF4 could further elevate the risk of thrombosis.

PF4 has a practical advantage over Klotho and young plasma: clinical-grade production of PF4 is already established, because PF4 is used as a diagnostic reagent for heparin-induced thrombocytopenia, and in early human trials PF4 itself neutralized heparin without serious adverse effects, although those studies were small and short. Klotho has a plasma half-life of roughly ten minutes, and young plasma remains a heterogeneous mixture with an inherent donor shortage. Further engineering of PF4 would need to preserve its binding to CXCR3 while reducing its affinity for heparin. That way the protective effects on brain and bone marrow would be retained, while one major source of thrombotic risk would be eliminated.